Automated cell culture equipment market seen reaching $4.03 billion by 2030

The automated cell culture equipment market is projected to grow from $2.32 billion in 2025 to $4.03 billion by 2030, driven by drug development, regenerative medicine and lab automation. Asia-Pacific is expected to be the fastest-growing region as pharmaceutical and biotech investment accelerates.

Why it matters: - Automated cell culture equipment is becoming more important as drug developers, biotech firms and labs seek faster, more reproducible cell cultivation. - The market’s growth points to rising demand for scalable tools that can support personalized medicine, regenerative therapies and cell and gene therapy pipelines.

What happened: - The Business Research Company released its Automated Cell Culture Equipment Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report projects the market will rise from $2.32 billion in 2025 to $2.6 billion in 2026. - The report forecasts the market will reach $4.03 billion by 2030. - The market is expected to grow at a 11.9% CAGR in the historical period and 11.6% CAGR over the forecast period.

The details: - Automated cell culture equipment includes laboratory systems that manage cell cultivation, upkeep and monitoring with minimal human involvement. - The systems combine robotics, sensors and software to improve reproducibility, efficiency and precision. - Automated workflows help reduce contamination risk and support large-scale experimentation. - The report cites rising demand in pharmaceutical and biologics research, broader drug discovery efforts, increasing complexity in cell-based assays and early lab adoption of automation as historical growth drivers. - Forecast growth is linked to investment in regenerative medicine, expanding cell and gene therapy pipelines, demand for scalable cell culture solutions, a stronger focus on reducing lab variability and AI-driven automation. - The report highlights trend lines including fully automated cell culture platforms, high-throughput cell processing, robotics, advanced imaging, closed-system workflows and greater standardization. - North America was the largest market in 2025. - Asia-Pacific is forecast to be the fastest-growing region. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Personalized medicine is a major demand driver because it depends on precise, high-throughput and reproducible cell culture for patient-specific therapies and customized drug testing. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 novel personalized treatments for rare diseases in 2023, up from six in 2022. - That jump suggests continued pressure on labs to automate more of the cell culture process. - The report’s added analytics, including market attractiveness scoring, TAM analysis and forecasting dashboards, signal a push toward more detailed planning tools for buyers and investors.

What's next: - The market is expected to keep expanding as pharmaceutical research and regenerative medicine investment increase. - Vendors will likely compete more on automation depth, contamination control, throughput and reproducibility. - Asia-Pacific’s growth should continue if regional biotech capacity and therapy pipelines keep expanding.

The bottom line: - Automated cell culture equipment is shifting from a niche lab upgrade to a core infrastructure category for next-generation drug development and cell-based research.